Research Paper Volume 15, Issue 1 pp 119—133
Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer
Figure 6. Association of the gene signature with response to molecular targeted therapy in pancreatic ductal adenocarcinoma. (A) IC50 of BMS-536924, Erlotinib, Foretinib, Linsitinib, and Sabutoclax exhibited a distinct effect on the low- and the high-risk cohorts. (B) Quantitative analysis showed that BMS-536924, Foretinib, Linsitinib, and Sabutoclax were more sensitive in the low-risk cancer cells, whereas Erlotinib was more effective in the high-risk cancer cells.